EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The utility and impact of digital endpoints for improving breast cancer outcomes

Ismail Jatoi iD, Jonathan A L Gelfond

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2024.2390056 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Ismail Jatoi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology and Endocrine Surgery, University of Texas Health Science Center, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Activities of Daily Living, Breast Neoplasms, Quality of Life, Wearable Electronic Devices. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In breast cancer clinical trials utilizing digital endpoints, wearable sensors record participants' health information during activities of daily living. These sensors are worn on the wrist or finger, placed as a skin patch or headband, or embedded on clothing. Data collected from wearable sensors form the basis of a digital endpoint, useful for determining effects of novel treatments on health outcomes, particularly quality-of-life outcomes. AREAS COVERED: References for this article were selected from a PubMed search spanning from 1 January 2017,to 1 July 2024, using the terms 'wearable sensors,' 'digital endpoints,' 'virtualtrials,' 'breast cancer.' Additional articles from the authors' personal collection of papers and reviewers suggestions were also used. EXPERT OPINION: Digital endpoints must be validated as proper surrogate measures for healthcare outcomes, prior to their use in breast cancer trials. Wearable sensors may introduce biases, such as 'missing not-at-random bias,' and perhaps even exacerbate disparities in healthcare outcomes if patients not comfortable with their use are excluded from clinical trials, or if the accuracy of sensors varies between racial and ethnic groups. Therefore, before embarking on trials with digital endpoints, validation studies are required, and limitations and risks of such trials need to be addressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activities of Daily LivingBreast NeoplasmsQuality of LifeWearable Electronic DevicesFemaleHumansBiasClinical Trials as TopicEndpoint DeterminationResearch Design

Stichwörter der Autor:innen

Breast cancerclinical trialsdigital endpointsscreeningtreatment

Autor:innen und Institutionen

  • Division of Surgical Oncology and Endocrine Surgery, University of Texas Health Science Center, San Antonio, TX, USA.
  • The Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA.

ORCID-Profile: Ismail Jatoi

Zitieren

APA

Jatoi, I., & Gelfond, J. A. L. (2025). The utility and impact of digital endpoints for improving breast cancer outcomes. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2390056

Vancouver

Jatoi I, Gelfond JAL. The utility and impact of digital endpoints for improving breast cancer outcomes. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2024.2390056

BibTeX
@article{Jatoi2025,
  author = {Jatoi, Ismail and Gelfond, Jonathan A L},
  title = {The utility and impact of digital endpoints for improving breast cancer outcomes},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2024.2390056}
}
Kostenlos starten →